Your shopping cart is currently empty

CAY10566 shows excellent cellular activity in blocking the conversion of saturated long-chain fatty acid-CoAs (LCFA-CoAs) to monounsaturated LCFA-CoAs in HepG2 cells (IC50=7.9 nM or 6.8 nM). CAY10566 is a potent, orally bioavailable and selective stearoyl-CoA desaturase1 (SCD1) inhibitor with IC50s of 4.5 and 26 nM in mouse and human enzymatic assays, respectively..

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $43 | In Stock | In Stock | |
| 5 mg | $140 | In Stock | In Stock | |
| 10 mg | $216 | In Stock | In Stock | |
| 25 mg | $392 | In Stock | In Stock | |
| 50 mg | $562 | In Stock | In Stock | |
| 100 mg | $788 | In Stock | In Stock | |
| 200 mg | $1,060 | In Stock | In Stock | |
| 1 mL x 10 mM (in DMSO) | $120 | In Stock | In Stock |
| Description | CAY10566 shows excellent cellular activity in blocking the conversion of saturated long-chain fatty acid-CoAs (LCFA-CoAs) to monounsaturated LCFA-CoAs in HepG2 cells (IC50=7.9 nM or 6.8 nM). CAY10566 is a potent, orally bioavailable and selective stearoyl-CoA desaturase1 (SCD1) inhibitor with IC50s of 4.5 and 26 nM in mouse and human enzymatic assays, respectively.. |
| Targets&IC50 | SCD1 (mouse):4.5 nM (IC50), SCD1 (human):26 nM (IC50) |
| In vitro | CAY10566 (0.0001-10 μM; 24 hours) concentration-dependently decreases Swiss 3T3 cell proliferation [3]. |
| In vivo | Upon the formation of detectable tumors, mice receive either a placebo or the SCD1 inhibitor CAY10566 (2.5 mg/kg orally twice daily). SCD1 inhibition demonstrates a more pronounced effect on Akt-driven tumors compared to Ras-driven tumors. Specifically, the average tumor volume on days 13 or 14 after treatment, compared to control tumors, was 0.5±0.04 for Akt-driven tumors and 0.67±0.05 for Ras-driven tumors (P=0.01 for Ras-Akt comparison, according to a two-tailed t-test) [4]. |
| Molecular Weight | 389.81 |
| Formula | C18H17ClFN5O2 |
| Cas No. | 944808-88-2 |
| Smiles | Cc1nnc(o1)-c1ccc(nn1)N1CCC(CC1)Oc1cc(F)ccc1Cl |
| Relative Density. | 1.369 g/cm3 (Predicted) |
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 26.84 mg/mL (68.85 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (5.13 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
DMSO
| |||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.